Cross-disease Modeling of Peripheral Blood Identifies Biomarkers of Type 2 Diabetes Predictive of Alzheimer's Disease

Overview

Journal bioRxiv

Date 2024 Dec 23

PMID 39713369

Authors

Brendan K Ball

Jee Hyun Park

Elizabeth A Proctor

Douglas K Brubaker

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes (T2D) is a significant risk factor for Alzheimer's disease (AD). Despite multiple studies reporting this connection, the mechanism by which T2D exacerbates AD is poorly understood. It is challenging to design studies that address co-occurring and comorbid diseases, limiting the number of existing evidence bases. To address this challenge, we expanded the applications of a computational framework called Translatable Components Regression (TransComp-R), initially designed for cross-species translation modeling, to perform cross-disease modeling to identify biological programs of T2D that may exacerbate AD pathology. Using TransComp-R, we combined peripheral blood-derived T2D and AD human transcriptomic data to identify T2D principal components predictive of AD status. Our model revealed genes enriched for biological pathways associated with inflammation, metabolism, and signaling pathways from T2D principal components predictive of AD. The same T2D PC predictive of AD outcomes unveiled sex-based differences across the AD datasets. We performed a gene expression correlational analysis to identify therapeutic hypotheses tailored to the T2D-AD axis. We identified six T2D and two dementia medications that induced gene expression profiles associated with a non-T2D or non-AD state. Finally, we assessed our blood-based T2DxAD biomarker signature in post-mortem human AD and control brain gene expression data from the hippocampus, entorhinal cortex, superior frontal gyrus, and postcentral gyrus. Using partial least squares discriminant analysis, we identified a subset of genes from our cross-disease blood-based biomarker panel that significantly separated AD and control brain samples. Our methodological advance in cross-disease modeling identified biological programs in T2D that may predict the future onset of AD in this population. This, paired with our therapeutic gene expression correlational analysis, also revealed alogliptin, a T2D medication that may help prevent the onset of AD in T2D patients.

References

Fischer S, Hanefeld M, Haffner S, Fusch C, Schwanebeck U, Kohler C . Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002; 39(3):105-10. DOI: 10.1007/s005920200027. View

Liu C, Tsai C, Deak F, Rogers J, Penuliar M, Sung Y . Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron. 2014; 84(1):63-77. PMC: 4199382. DOI: 10.1016/j.neuron.2014.08.048. View

Gudala K, Bansal D, Schifano F, Bhansali A . Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2014; 4(6):640-50. PMC: 4020261. DOI: 10.1111/jdi.12087. View

Davis S, Meltzer P . GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007; 23(14):1846-7. DOI: 10.1093/bioinformatics/btm254. View

Fuster J, Zuriaga M, Ngo D, Farb M, Aprahamian T, Yamaguchi T . Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes. 2014; 64(4):1235-48. PMC: 4375084. DOI: 10.2337/db14-1164. View

Rom S, Zuluaga-Ramirez V, Gajghate S, Seliga A, Winfield M, Heldt N . Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. Mol Neurobiol. 2018; 56(3):1883-1896. PMC: 6320739. DOI: 10.1007/s12035-018-1195-5. View

Cheng G, Huang C, Deng H, Wang H . Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012; 42(5):484-91. DOI: 10.1111/j.1445-5994.2012.02758.x. View

Cereijo R, Quesada-Lopez T, Gavalda-Navarro A, Tarasco J, Pellitero S, Reyes M . The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans. Int J Obes (Lond). 2021; 45(3):706-710. DOI: 10.1038/s41366-020-00732-y. View

Vohra M, Sharma A, Mallya S, Prabhu N, Jayaram P, Nagri S . Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes. J Endocrinol Invest. 2022; 46(6):1205-1218. PMC: 10185588. DOI: 10.1007/s40618-022-01989-y. View

10.

Holtta M, Minthon L, Hansson O, Holmen-Larsson J, Pike I, Ward M . An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. J Proteome Res. 2014; 14(2):654-63. DOI: 10.1021/pr501076j. View

11.

Min J, Ha S, Yang S, Kang M, Jeong D, Min K . Chronic Status of Serum Albumin and Cognitive Function: A Retrospective Cohort Study. J Clin Med. 2022; 11(3). PMC: 8836994. DOI: 10.3390/jcm11030822. View

12.

Xie Z, Kropiwnicki E, Wojciechowicz M, Jagodnik K, Shu I, Bailey A . Getting Started with LINCS Datasets and Tools. Curr Protoc. 2022; 2(7):e487. PMC: 9326873. DOI: 10.1002/cpz1.487. View

13.

Berchtold N, Coleman P, Cribbs D, Rogers J, Gillen D, Cotman C . Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging. 2013; 34(6):1653-61. PMC: 4022280. DOI: 10.1016/j.neurobiolaging.2012.11.024. View

14.

Brown A, Palsgaard J, Borup R, Avery P, Gunn D, De Meyts P . p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2014; 308(1):E63-70. PMC: 4281683. DOI: 10.1152/ajpendo.00115.2014. View

15.

Wang S, Zhang C, Sheng X, Zhang X, Wang B, Zhang G . Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases. J Clin Neurosci. 2014; 21(5):810-4. DOI: 10.1016/j.jocn.2013.08.017. View

16.

Shen R, Zhao X, He L, Ding Y, Xu W, Lin S . Upregulation of RIN3 induces endosomal dysfunction in Alzheimer's disease. Transl Neurodegener. 2020; 9(1):26. PMC: 7301499. DOI: 10.1186/s40035-020-00206-1. View

17.

Chen R, Ovbiagele B, Feng W . Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci. 2016; 351(4):380-6. PMC: 5298897. DOI: 10.1016/j.amjms.2016.01.011. View

18.

Pontzer H, Yamada Y, Sagayama H, Ainslie P, Andersen L, Anderson L . Daily energy expenditure through the human life course. Science. 2021; 373(6556):808-812. PMC: 8370708. DOI: 10.1126/science.abe5017. View

19.

Palazzuoli A, Iacoviello M . Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2022; 28(3):585-596. PMC: 10140137. DOI: 10.1007/s10741-022-10238-6. View

20.

Ball B, Kuhn M, Fleeman Bechtel R, Proctor E, Brubaker D . Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer's disease-associated metabolites. Sci Rep. 2024; 14(1):12743. PMC: 11148169. DOI: 10.1038/s41598-024-62155-3. View